Latest Press releases
HepaRegeniX GmbH achieves successful proof of efficacy in acute liver disease models for selected MKK4 inhibitors
Preclinical data demonstrate efficacy of MKK4 inhibitors in liver regeneration and experimental acute and chronic liver disease models...
HepaRegeniX GmbH secures Series B Financing in excess of € 11 Mio. to advance first drug candidate to the clinic
Preclinical data demonstrate efficacy of MKK4 inhibitors in liver regeneration and experimental acute and chronic liver disease models...
HepaRegeniX GmbH announces management changes: Dr. Michael Lutz appointed as new CEO/Managing Director
Dr. Lutz is an experienced biotech entrepreneur who has spent the last 15 years at executive management positions with several Life Sciences companies...